Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 12/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | FADS1 | O60427 | 2/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.36 |
| ▸ | CALML3 | P27482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14490011 | 0.85 | GRM2 (0.58) | GRM2MAOAMAOBFADS1CALML3 | |
| SCHEMBL8860802 | 0.81 | GRM2 (0.55) | GRM2MAOAMAOBFADS1 | |
| SCHEMBL8594767 | 0.81 | GRM2 (0.55) | GRM2MAOAMAOBFADS1 | |
| SCHEMBL1077611 | 0.70 | GRM2 (0.70) | GRM2MAOAMAOBFADS1CALML3 | |
| SCHEMBL1032517 | 0.70 | MAOA (0.71) | GRM2MAOAMAOBFADS1CALML3 | |
| SCHEMBL1557298 | 0.70 | MAOA (0.71) | GRM2MAOAMAOBFADS1CALML3 | |
| SCHEMBL3087781 | 0.70 | MAOA (0.71) | GRM2MAOAMAOBFADS1CALML3 | |
| SCHEMBL4163689 | 0.70 | GRM2 (0.60) | GRM2MAOAMAOBFADS1 | |
| SCHEMBL3181922 | 0.70 | GRM2 (0.60) | GRM2MAOAMAOBFADS1 | |
| SCHEMBL8594769 | 0.68 | MAOA (0.54) | GRM2MAOAMAOBFADS1CALML3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070149463-A1 | Bifunctional macrolide heterocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. | 2007-06-28 | — | — | US | disclosed |
| US-20070149463-A1 | Bifunctional macrolide heterocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149463-A1 | Bifunctional macrolide heterocyclic compounds and methods of making and using the same | PAICS, MAP2K4, GIPR | GRM2 4501/4885MAOA 1209/4885MAOB 1137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.